form8k.htm
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
_______________
Form
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of
report (date of earliest event reported):
June
4, 2008
SCOLR
Pharma, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-31982
|
91-1689591
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File No.)
|
(I.R.S.
Employer Identification No.)
|
3625
132nd Avenue SE, Suite 400
Bellevue,
WA 98006
(Address
of principal executive offices)
(425)
373-0171
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
£ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
£ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Item
7.01 Regulation FD Disclosure.
Representatives
of SCOLR Pharma, Inc. will use the materials attached hereto as Exhibit 99.1 in
investor presentations from time to time. We have also posted the presentation
materials on our company website at www.scolr.com.
Please
refer to page 2 of Exhibit 99.1 for a discussion of certain forward-looking
statements included in the presentation materials, including without limitation
information about the status of our product development programs and timelines.
These forward-looking statements involve risks and uncertainties, including
activities, events or developments that we expect, believe or anticipate will or
may occur in the future. A number of factors could cause actual results to
differ from those indicated in the forward-looking statements, including our
ability to successfully develop new formulations and complete research and
development, including pre-clinical and clinical studies, our ability to raise
additional funds, the continuation of arrangements with our product development
partners and customers, competition, government regulation and approvals, and
general economic conditions. In order to obtain regulatory approvals for the
commercial sale of potential products utilizing our CDT platform, we may be
required to complete clinical trials in humans to demonstrate the safety and
efficacy, or in certain cases, the bioequivalence, of the products. However, we
may not be able to commence or complete these clinical trials in any specified
time period, or at all, either because the appropriate regulatory agency objects
or for other reasons. We plan to continue the costly process of simultaneously
conducting clinical trials and preclinical research for multiple product
candidates. Additional assumptions, risks and uncertainties are described in
detail in our registration statements, reports and other filings with the
Securities and Exchange Commission. Such filings are available on our website or
at www.sec.gov.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
|
Exhibit
No.
|
Description
|
|
|
|
|
|
Presentation
materials for the investor presentation by SCOLR Pharma,
Inc.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
SCOLR
PHARMA, INC.
|
|
|
|
|
|
|
|
Dated: June
4, 2008
|
By:
|
/s/
Daniel O. Wilds
|
|
|
|
Daniel
O. Wilds
President
and Chief Executive Officer
|
3